Bayer raises guidance as net income drops on YAZ risk provision
This article was originally published in Scrip
Executive Summary
German group Bayer saw sales rise 10% in the second quarter to a record €10.18 billion, thanks in part to positive currency effects. The currency and portfolio adjusted increase was 5%. Bayer's pharmaceutical sales rose 4% (adjusted) to €2.69 billion, helped by growth in North America and China, while Western Europe declined slightly.